Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Palbociclib
Related studies linked through entity extraction aliases.
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- Status
- RECRUITING
- Phase
- PHASE3
Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients.
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
- Status
- RECRUITING
- Phase
- PHASE2
Palbociclib and Pembrolizumab in Sarcoma
- Status
- RECRUITING
- Phase
- PHASE1
Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.
- Status
- COMPLETED
- Phase
- N/A
Palbociclib Induced Neutropenia; Risk Factors and Treatment Outcome in Metastatic Breast Cancer Patients
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
- Status
- RECRUITING
- Phase
- PHASE3
Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms
- Status
- RECRUITING
- Phase
- PHASE1
A Study to Understand the Use of Palbociclib in Canadian Patients With Breast Cancer That Has Spread to Other Organs
- Status
- COMPLETED
- Phase
- N/A
OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE4
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
- Status
- TERMINATED
- Phase
- PHASE2
Study of AVZO-021 in Patients With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction
- Status
- RECRUITING
- Phase
- PHASE2
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC
- Status
- RECRUITING
- Phase
- PHASE2
First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
- Status
- RECRUITING
- Phase
- PHASE2